Cancer's 'rogue DNA' relies on two proteins to prevent and repair breaks
· Medical Xpressby Ian Demsky, Memorial Sloan Kettering Cancer Center
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Researchers at Memorial Sloan Kettering Cancer Center (MSK) and their colleagues have discovered that a type of rogue DNA found in aggressive cancers has a hidden structural weakness—and that blocking a single repair protein can cause it to fall apart, suggesting a new therapeutic opportunity.
This rogue DNA is called extrachromosomal DNA, or ecDNA, and it is found in roughly 1 in 6 human cancers. ecDNA consists of circular pieces of DNA that sit outside normal chromosomes and drive the amplification of cancer-causing genes.
The presence of ecDNA has been linked to faster tumor growth, resistance to treatment and poorer survival—but scientists haven't been clear on how cancer cells keep this unstable DNA intact.
Now the lab of Agnel Sfeir, Ph.D., at MSK's Sloan Kettering Institute and collaborators have uncovered a two-part protection system that cancer cells use to prevent and repair breaks in ecDNA. They also show that ecDNA carries a structural vulnerability that could potentially be targeted therapeutically. Their findings were published Sept. 23 in Nature.
Finding ecDNA's structural weakness
The team—co-led by radiation oncologist David Billing, MD, Ph.D., and graduate student Monica Selvaraj—found that repetitive sequences in ecDNA are structural weak points where it is prone to breaking.
Specifically, the team identified stretches of alternating T and A letters in the DNA code—called TA repeats—that tend to fold into unusual, cross-shaped structures. These structures are particularly fragile, leading to breaks that the cancer cell must repair quickly.
"We were surprised to find that ecDNA has a built-in fragility," Sfeir says. "The circular shape allows genes to rapidly amplify and gives cancer cells a growth advantage, but it is also inherently prone to breaking. That means cancer cells depend on repair to keep them intact, and that dependency is something we may be able to exploit."
Uncovering ecDNA's two-pronged repair system
Cancer cells depend on a key repair protein—polymerase theta, or Polθ—to patch these breaks and keep ecDNA stable, the researchers found. They also identified a second protein called FANCM that serves as a first line of defense by preventing breaks from forming in the first place.
Together, the two proteins act as a two-pronged protection system: FANCM smooths out the problematic DNA structures before they break, while Polθ fixes breaks after they happen.
When the researchers blocked Polθ with an experimental inhibitor, ecDNA became unstable, accumulated damage and was progressively lost from cancer cells—while cells without ecDNA were largely unaffected. The team saw this effect across several cancer cell lines, including prostate, gastric and colorectal cancers.
And the findings appear to hold true beyond the lab, too. An analysis of large human tumor sequencing datasets showed that the same TA repeat regions where breaks cluster are also common sites for DNA rearrangements in patient tumors across multiple cancer types.
Toward clinical applications
Together, the findings suggest that Polθ inhibitors—several of which are already in clinical development—could offer a targeted strategy to destabilize ecDNA and potentially help overcome therapy resistance in some of the hardest-to-treat cancers.
And combining a Polθ inhibitor with depletion of FANCM had an even stronger effect, the researchers note, pointing toward possible combination therapy strategies.
"This gives us a new way to think about targeting ecDNA," says Sfeir, who holds the PaineWebber Chair in Cancer Genetics at MSK. "There's still much to learn, but we're excited to see where the discovery of this vulnerability can take us."
Publication details
David Billing et al, MMEJ repair of breaks at TA repeats maintains ecDNA and cancer fitness, Nature (2026). DOI: 10.1038/s41586-026-11048-8
Journal information: Nature
Key medical concepts
Clinical categories
OncologyClinical genetics Provided by Memorial Sloan Kettering Cancer Center Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Cancer's 'rogue DNA' relies on two proteins to prevent and repair breaks (2026, September 23) retrieved 23 September 2026 from https://medicalxpress.com/news/2026-09-cancer-rogue-dna-proteins.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.